Treatment and Prognosis of Male Breast Cancer: A Multicentric,
Retrospective Study Over 11 Years in the Czech Republic

J 2024

Treatment and Prognosis of Male Breast Cancer: A Multicentric, Retrospective Study Over 11 Years in the Czech Republic

BIELCIKOVA, Zuzana, Miloš HOLÁNEK, Iveta SELINGEROVÁ, Ondrej SOREJS, Iveta KOLAROVA et. al.

Základní údaje

Originální název

Treatment and Prognosis of Male Breast Cancer: A Multicentric, Retrospective Study Over 11 Years in the Czech Republic

Autoři

Vydání

Oncologist, OXFORD, OXFORD UNIV PRESS, 2024, 1083-7159

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 5.800 v roce 2022

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1093/oncolo/oyae031

UT WoS

001176836200001

Klíčová slova anglicky

male breast cancer; epidemiology; genetic testing; prognosis; retrospective study

Štítky

14110811

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 19. 8. 2024 10:35, Mgr. Tereza Miškechová

Anotace

V originále

Purpose: Male breast cancer (MBC) is a rare, but increasingly common disease, and lacks prospective studies. Collaborative efforts are needed to understand and address MBC, including its prognosis, in different countries. Methods: We retrospectively reviewed the clinical, histopathological, and molecular-genetic characteristics, treatments, and survival outcomes of MBC diagnosed between 2007 and 2017 in the Czech Republic. Prognostic factors of overall survival (OS), recurrence-free interval (RFi), and breast cancer-specific mortality (BCSM) were analyzed and indirectly compared to international data. Results: We analyzed 256 patients with MBC (median age 66 years), including 12% with de novo metastatic (M1). Of 201 non-metastatic (M0) patients, 6% were <40 years old, 29% had stage I, 55% were cN0, and 54% underwent genetic testing. Overall, 97% of tumors had estrogen receptor expression >= 10%, 61% had high Ki67 index, 40% were high-grade (G3), and 68% were luminal B-like (HER2-negative). Systemic therapies included endocrine therapy (90%) and chemotherapy (53%). Few (5%) patients discontinued adjuvant endocrine therapy for reasons other than disease relapse or death. Patients treated with aromatase inhibitors alone had significantly shorter RFi (P < .001). OS, RFi, and BCSM were associated with disease stage, T stage, N stage, progesterone receptor expression, grade, and Ki67 index. Median OS reached 122 and 42 months in M0 and de novo M1 patients, respectively. Conclusion: Due to the rarity of MBC, this study highlights important findings from real clinical practice. Although the number of patients with MBC with unfavorable features was higher in this Czech dataset than in international studies, the prognosis remains consistent with real-world evidence.

Citovat

BIELCIKOVA, Zuzana, Miloš HOLÁNEK, Iveta SELINGEROVÁ, Ondrej SOREJS, Iveta KOLAROVA, Renata SOUMAROVA, Jan PROKS, Lucie REIFOVA, Vlastimila CMEJLOVA, Lenka LINKOVA, Michaela ZABOJNIKOVA, Martina CHODACKA, Lucie JANOVSKA, Lenka LISNEROVA, Karolina KASPAROVA, Denisa POHANKOVA a Lubos PETRUZELKA. Treatment and Prognosis of Male Breast Cancer: A Multicentric, Retrospective Study Over 11 Years in the Czech Republic. Oncologist. OXFORD: OXFORD UNIV PRESS, 2024, 13 s. ISSN 1083-7159. Dostupné z: https://dx.doi.org/10.1093/oncolo/oyae031.

@article{2407803,
   author = {Bielcikova, Zuzana and Holánek, Miloš and Selingerová, Iveta and Sorejs, Ondrej and Kolarova, Iveta and Soumarova, Renata and Proks, Jan and Reifova, Lucie and Cmejlova, Vlastimila and Linkova, Lenka and Zabojnikova, Michaela and Chodacka, Martina and Janovska, Lucie and Lisnerova, Lenka and Kasparova, Karolina and Pohankova, Denisa and Petruzelka, Lubos},
   article_location = {OXFORD},
   doi = {http://dx.doi.org/10.1093/oncolo/oyae031},
   keywords = {male breast cancer; epidemiology; genetic testing; prognosis; retrospective study},
   language = {eng},
   issn = {1083-7159},
   journal = {Oncologist},
   title = {Treatment and Prognosis of Male Breast Cancer: A Multicentric, Retrospective Study Over 11 Years in the Czech Republic},
   url = {https://academic.oup.com/oncolo/article/29/6/e750/7618160?login=true},
   year = {2024}
}

TY  - JOUR
ID  - 2407803
AU  - Bielcikova, Zuzana - Holánek, Miloš - Selingerová, Iveta - Sorejs, Ondrej - Kolarova, Iveta - Soumarova, Renata - Proks, Jan - Reifova, Lucie - Cmejlova, Vlastimila - Linkova, Lenka - Zabojnikova, Michaela - Chodacka, Martina - Janovska, Lucie - Lisnerova, Lenka - Kasparova, Karolina - Pohankova, Denisa - Petruzelka, Lubos
PY  - 2024
TI  - Treatment and Prognosis of Male Breast Cancer: A Multicentric, Retrospective Study Over 11 Years in the Czech Republic
JF  - Oncologist
PB  - OXFORD UNIV PRESS
SN  - 10837159
KW  - male breast cancer
KW  - epidemiology
KW  - genetic testing
KW  - prognosis
KW  - retrospective study
UR  - https://academic.oup.com/oncolo/article/29/6/e750/7618160?login=true
N2  - Purpose: Male breast cancer (MBC) is a rare, but increasingly common disease, and lacks prospective studies. Collaborative efforts are needed to understand and address MBC, including its prognosis, in different countries. Methods: We retrospectively reviewed the clinical, histopathological, and molecular-genetic characteristics, treatments, and survival outcomes of MBC diagnosed between 2007 and 2017 in the Czech Republic. Prognostic factors of overall survival (OS), recurrence-free interval (RFi), and breast cancer-specific mortality (BCSM) were analyzed and indirectly compared to international data. Results: We analyzed 256 patients with MBC (median age 66 years), including 12% with de novo metastatic (M1). Of 201 non-metastatic (M0) patients, 6% were <40 years old, 29% had stage I, 55% were cN0, and 54% underwent genetic testing. Overall, 97% of tumors had estrogen receptor expression >= 10%, 61% had high Ki67 index, 40% were high-grade (G3), and 68% were luminal B-like (HER2-negative). Systemic therapies included endocrine therapy (90%) and chemotherapy (53%). Few (5%) patients discontinued adjuvant endocrine therapy for reasons other than disease relapse or death. Patients treated with aromatase inhibitors alone had significantly shorter RFi (P < .001). OS, RFi, and BCSM were associated with disease stage, T stage, N stage, progesterone receptor expression, grade, and Ki67 index. Median OS reached 122 and 42 months in M0 and de novo M1 patients, respectively. Conclusion: Due to the rarity of MBC, this study highlights important findings from real clinical practice. Although the number of patients with MBC with unfavorable features was higher in this Czech dataset than in international studies, the prognosis remains consistent with real-world evidence.
ER  -

BIELCIKOVA, Zuzana, Miloš HOLÁNEK, Iveta SELINGEROVÁ, Ondrej SOREJS, Iveta KOLAROVA, Renata SOUMAROVA, Jan PROKS, Lucie REIFOVA, Vlastimila CMEJLOVA, Lenka LINKOVA, Michaela ZABOJNIKOVA, Martina CHODACKA, Lucie JANOVSKA, Lenka LISNEROVA, Karolina KASPAROVA, Denisa POHANKOVA a Lubos PETRUZELKA. Treatment and Prognosis of Male Breast Cancer: A Multicentric, Retrospective Study Over 11 Years in the Czech Republic. \textit{Oncologist}. OXFORD: OXFORD UNIV PRESS, 2024, 13 s. ISSN~1083-7159. Dostupné z: https://dx.doi.org/10.1093/oncolo/oyae031.

Podrobný výpis o publikaci